Error in the Figure
- PMID: 31294757
- PMCID: PMC6624819
- DOI: 10.1001/jamaoncol.2019.2255
Error in the Figure
Erratum for
-
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.JAMA Oncol. 2019 Jul 1;5(7):1060-1062. doi: 10.1001/jamaoncol.2019.0869. JAMA Oncol. 2019. PMID: 31046065 Free PMC article. Clinical Trial.
References
-
- De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J; CORE-ARV-CTC and ProBIO Investigators . Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer [published online May 2, 2019]. JAMA Oncol. doi:10.1001/jamaoncol.2019.0869 - DOI - PMC - PubMed
